Scotland · NHS Scotland MSAN
Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches
MSAN(2025)51 · Level 3 · issued 09 Dec 2025
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| 1. Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches are in limited supply | Limited supply | — |
| 2. Rivastigmine 13.3mg/24hours transdermal patches remain available but cannot support an | Available — cannot support uplift | — |
| 3. Rivastigmine (Zeyzelf) twice weekly 4.6 mg/24hours transdermal patch is out of stock until w/c | Out of stock | w/c |
| 4. Rivastigmine (Zeyzelf) twice weekly 9.5 mg/24hours transdermal patch remains available but | Available | — |
| cannot support uplift in demand. | Available — cannot support uplift | — |
| 5. Alternative formulations of acetylcholinesterase (AChE) inhibitors remain available, except for | Available | — |
| galantamine modified release capsules, which are in limited supply (see Additional Information). | Limited supply | — |
| Alzest® Discontinued Discontinued Discontinued | Discontinued | — |
| stock, but the 4.6mg/24hours strength is out of stock until w/c 15/12/25. | Out of stock | w/c 15/12/25 |
| 11. Of the AChE inhibitors, only rivastigmine is available as a transdermal formulation. | Available | — |
| you need to register with the SPS website. Registration for access to the website is available to | Available | — |
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.